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Preeclampsia is a relatively common complication of preg-nancy with a prevalence of 3% to 5%.1 It is the leading 
cause of morbidity and mortality for pregnant women in the 
developed world and also has a significant economic burden 
on healthcare systems.2 Despite many decades of exhaus-
tive research efforts, we have yet to reach a unifying theory 
explaining why and how preeclampsia occurs in women with 
no apparent risk factors. The placenta has been the major, 
long-standing focus of preeclampsia research—not surprising 
because placental lesions associated with preeclampsia were 
described as early as 1940.3 The triad of inadequate placenta-
tion, placental insufficiency, and vascular reactivity cascade 
is the most acknowledged explanation of the pathology un-
derlying preeclampsia. However, clinical findings support-
ing this triad are only found in a minority of all preeclamptic 
pregnancies, and pathological placental lesions in support of 
this hypothesis may not be as specific as previously thought.4,5 
The fact that our best hypothesis fails to explain the majority 
of preeclampsia cases led many researchers to take a broader 
view and look for other factors which may be associated with 
this serious and relatively common pregnancy-related dis-
order. We have known for some time that women with pree-
clampsia have poor long-term cardiovascular outcome, but the 
emerging evidence now suggests the impact of preeclampsia 
on maternal health is more immediate and profound than pre-
viously suspected.6–14 Moreover, preeclampsia and cardiovas-
cular diseases share antecedents which were often thought to 
be a spurious association; however, many epidemiological 
studies now suggest that some cardiovascular risk factors also 
increase the risk for developing preeclampsia.15–18 Considering 
that cardiovascular problems associated with preeclampsia are 
observed both before and after the index pregnancy, it is rea-
sonable to assume the cardiovascular system may not just be 
the victim of poor placentation in preeclampsia, but actually 
play a pivotal role in the pathogenesis of preeclampsia. More 
recent research has examined the association between the 
cardiovascular system and preeclampsia in an effort to build 
an overarching hypothesis to explain the pathophysiology of 
the disorder.19–22 These works have highlighted the fact that 
postpartum cardiovascular maternal health after preeclampsia 
is a largely neglected area of research and that women with 
preeclampsia may benefit from screening, follow-up, and 
intervention. In this review, we summarize some of the key 
evidence and clinical implications of the association of pree-
clampsia with the cardiovascular system.
Risk Factors for Developing Preeclampsia
Preeclampsia and cardiovascular diseases share genetic and 
nongenetic risk factors. In an umbrella review of published 
reviews, Giannakou et al16 suggested presence of obesity, 
smoking, psychological stress, chronic kidney disease, pol-
ycystic ovarian disease, and PAI-1 polymorphism were con-
sistently associated with preeclampsia. A recent genome-wide 
association study has implicated a locus near the fetal FLT1 
region for the development of preeclampsia supporting the 
hypothesis that a placental isoform of sFlt-1 (soluble fms-
like tyrosine kinase-1) is involved in the pathophysiology of 
the disease.23 A recent candidate gene association study in a 
Finnish cohort of preeclamptic mothers has also confirmed the 
involvement of the sFlt-1 gene in preeclampsia.24 Curiously, 
smoking is also paradoxically associated with an apparent 
reduction in the prevalence of mild preeclampsia at term.25 
Although nicotine is associated with short-term vasoconstric-
tion, carbon monoxide from smoking has been shown to lower 
the production of preeclampsia mediators (sFlt-1 and soluble 
endoglin) in endothelial cells and placental cultures.26 Carbon 
monoxide also has a more protracted hypotensive effect of 
2 to 3 mm Hg, which would prevent some pregnancies from 
meeting the diastolic blood pressure threshold (90 mm Hg) 
for a diagnosis of preeclampsia.27 Even principally hormonal 
disorders, such as polycystic ovarian disease and premature 
ovarian failure (with ovum donation pregnancies), may affect 
increased preeclampsia risk by virtue that these disorders 
confer increased cardiovascular risk outside pregnancy.28
Several large cohort studies have also suggested triglyc-
eride levels, cholesterol/HDL (high-density lipoprotein) 
ApoE concentrations, and ApoB/Apo A1 ratio were signif-
icantly different in preeclamptic pregnancies.17,18 Diabetes 
mellitus, prepregnancy weight, and maternal weight gain 
in pregnancy are independent risk factors for preeclampsia 
which may explain why metformin may be effective in re-
ducing the prevalence of preeclampsia.29,30 Women with 
chronic hypertension, previous history of acute kidney in-
jury, or a family history of myocardial infarction before the 
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age of 60 years have an increased risk of preeclampsia.18,31 
Previous preeclampsia is a risk factor for recurrence in a 
subsequent pregnancy, perhaps because of an inability of 
cardiovascular system to recover from preeclampsia as car-
diovascular profiles in women with recurrent preeclampsia 
are poorer compared with those who have a normal preg-
nancy subsequently. Women with recurrent preeclampsia 
have increased carotid intima-media thickness and peak mi-
tral filling early diastole/atrial contraction ratio, as well as 
lower cardiac output (CO) and left ventricular mass, com-
pared with women with a normal follow-on pregnancy.31–35 
In a landmark study, Romundstad et al15 assessed in a large 
epidemiological study whether the predisposition of pre-
eclamptic women to increased risk for cardiovascular di-
sease later in life can be attributed to pregnancy factors or 
to prepregnancy risk factors that are shared by both disor-
ders. Their results suggested that the positive association of 
preeclampsia postpartum cardiovascular risk is due largely 
to shared prepregnancy risk factors rather than reflecting a 
direct influence of preeclamptic pregnancy on the maternal 
cardiovascular system. That all of these risk factors are also 
known to be correlated with cardiovascular morbidity in non-
pregnant adults (Table 1) is consistent with the hypothesis 
that poor cardiovascular reserve predisposes to the placen-
tally mediated disorder of preeclampsia (Figure 1).36–38
Early Pregnancy Cardiovascular Changes 
Related to Preeclampsia
Endothelium-derived vasoconstrictors are core components 
of preeclampsia pathophysiology, with studies demonstrat-
ing that derangement in Ang II (angiotensin-II), endothe-
lin-1, and thromboxane A2 physiology occur long before 
onset of signs and symptoms of preeclampsia.39–46 Some of 
the biological consequences of these processes—higher blood 
pressure and peripheral arterial waveform resistance—are 
also observed long before the onset of preeclampsia. Both of 
these parameters (maternal mean arterial blood pressure and 
uterine artery resistance) are the most influential first trimester 
predictive biomarkers for preeclampsia.47 Importantly, other 
maternal peripheral arteries (ie, ophthalmic artery, brachial 
artery) also show signs of impaired function in early preg-
nancy reflecting abnormal generalized vascular physiology 
in preeclampsia rather than localized a vascular defect in the 
uteroplacental circulation as initially presumed.48–51 Recently, 
Foo et al52 demonstrated that women who subsequently devel-
oped preeclampsia have decreased CO and increased periph-
eral resistance even before conception when compared with 
healthy pregnancies. Similar findings together with cardiac 
remodeling and hypertrophy are reported for normal women 
at midgestation or women with chronic hypertension who 
later develop preeclampsia.53,54 These findings not only sup-
port the hypothesis for a shared vascular predisposition to pre-
eclampsia and cardiovascular morbidity in the nonpregnant 
population but also open up the possibility that investigating 
cardiovascular function may help further elucidate the patho-
physiology and clinical consequences of preeclampsia.38,55,56 
In support of a shared cardiovascular predisposition to pre-
eclampsia and cardiovascular disease, current prophylaxis 
and pharmacological management of preeclampsia involves 
principally compounds familiar to the field of cardiology—
aspirin, statins, metformin, nitric oxide donors, and antihy-
pertensive agents. Interestingly, statins have widespread use 
for the primary and secondary prevention of coronary disease 
and are also associated with reduced levels of circulating pre-
eclampsia biomarkers in animal studies.57 A preliminary study 
suggested pravastatin use is safe during pregnancy and a larger 
trial with dose escalation may be feasible to test whether it 
is effective in prevention/treatment of preeclampsia.58 Use of 
nitric oxide donors are associated with reduction in total vas-
cular resistance and reduced rate of adverse outcome in hyper-
tensive pregnancies.59
Cardiovascular System in Pregnancy and 
Preeclampsia
Hemodynamic changes during pregnancy include a progres-
sive increase in CO and a decrease in the systemic vascular 
resistance leading to a high-volume, low-resistance circu-
lation. These changes peak in the midthird trimester before 
CO falls, and systemic vascular resistance increases towards 
40 weeks’ gestation.60,61 The alteration in late pregnancy he-
modynamics is biologically paradoxical when considering 
that the respiratory and metabolic demands of the maternal-
fetal unit increases exponentially with advancing gestation.62 
Echocardiographic studies of uncomplicated normal preg-
nancies have demonstrated an excessive increase in the left 
ventricular mass and remodeling with associated diastolic 
dysfunction in a small but significant proportion of women at 
term—all of which revert to normal postpartum.63,64 For this 
reason, pregnancy has been described as a stress test which 
unmasks women who have poor cardiovascular reserve or 
dysfunction.65
Maternal echocardiography studies in preeclampsia have 
demonstrated significant cardiac dysfunction both before and 
Table 1. Risk Categories and Factors in Common for Both Preeclampsia and 
Cardiovascular Disease
Physical Advanced maternal age
Weight (prepregnancy and pregnancy weight gain)
Ethnicity (black/Afro-Caribbean or Hispanic)
Environmental Smoking
Sedentary lifestyle
Psychological stress
Hormonal Polycystic ovarian syndrome
Premature ovarian failure (ovum donation pregnancy)
Autoimmune Systemic lupus erythematosus
Antiphospholipid syndrome
Metabolic Diabetes mellitus (prepregnancy and gestational)
Renal Chronic kidney disease
History of acute kidney injury
Cardiovascular Chronic hypertension
Abnormal serum lipid profile
History of placental dysfunction (preeclampsia or fetal 
growth restriction)
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at clinical onset of preeclampsia. Valensise et al66 first dem-
onstrated that CO was significantly lower in early-onset (<34 
weeks) preeclampsia compared with late-onset (≥34 weeks) 
preeclampsia. Their findings were later confirmed and ex-
panded on with the work of Melchiorre et al53 who showed 
that preeclampsia was also associated with abnormal car-
diac geometry and diastolic dysfunction in the majority of 
women who developed preeclampsia. A recent systematic 
review summarized 36 studies of maternal cardiovascular 
function involving 815 women with preeclampsia, demon-
strating that increased vascular resistance and left ventric-
ular mass were the most consistent findings in preeclampsia 
(Table 2).67 Differentiating features from normal pregnancy 
were left ventricular wall thickness of ≥1.0 cm, exaggerated 
reduction in early diastole/atrial contraction, and lateral e′ 
of <14 cm/s which are the markers of diastolic dysfunction. 
Reduced stroke volume, diastolic dysfunction, and left ven-
tricular remodeling are most marked in severe and early-onset 
preeclampsia and are associated with adverse maternal and 
fetal outcomes—irrespective of the conventional classifica-
tion of preeclampsia based on clinical severity or gestation 
of onset.67–73 These findings demonstrate that even apparently 
normal pregnancy presents a significant strain on the maternal 
cardiovascular system and that in women with evidence of 
worsening cardiovascular maladaptation, preeclampsia is the 
recognized clinical phenotype (Figure 2).
Putative Roles for Cardiovascular Assessment 
in the Management of Preeclampsia
The evaluation and control of hypertension is established in 
preeclampsia management. The potential impact of routine 
echocardiography in high-risk pregnancy remains to be estab-
lished mainly because of lack of access and practicalities of 
undertaking these investigations in the emergency obstetric 
setting. However, noninvasive CO monitoring (such as with 
NICOM bioreactance and USCOM Doppler monitors) pre-
sent alternative methods for monitoring of maternal hemody-
namic parameters.74 Noninvasive monitors hold a significant 
edge over echocardiography by being more practical and 
requiring little training to operate competently. Although non-
invasive cardiac monitors are most often used in an intensive 
care unit setting, recently, they have been assessed and vali-
dated in pregnancy. Noninvasive monitors show good agree-
ment with transthoracic echocardiography for the assessment 
of CO but only in the third trimester.74 At earlier gestations 
or postnatally, the levels of agreement were poor indicating 
that indices derived from noninvasive monitors cannot be 
Figure 1. Diagram illustrating the interaction between maternal 
cardiovascular function and placental function, maternal health, and fetal 
well-being. Placental oxidative stress or hypoxia is related to the relative 
balance of cardiovascular functional reserve and the cardiovascular 
volume/resistance load of pregnancy. The final common pathway that 
results in the signs and symptoms of preeclampsia involves the release of 
placental vasoactive substances. PIGF indicates placenta growth factor; 
and sFLT, soluble fms-like tyrosine kinase. 
Table 2. Summary of Left-Sided Cardiovascular Findings at Presentation With 
Preeclampsia
Cardiovascular Index
Term 
Preeclampsia
Preterm 
Preeclampsia
Hemodynamic
 Cardiac index, L/(min·m2) 2.8 2.6
 TVRI, [dyn·s−1·cm−5]/m2 800 1200
LV geometry
 Concentric remodeling 50% 50%
 Concentric hypertrophy 20% 5%
 Eccentric hypertrophy … 20%
Myocardial function
 Impaired relaxation 60% 85%
 Impaired contractility 40% 60%
Chamber function
 Diastolic dysfunction 40% 50%
 Systolic dysfunction … 25%
Values are given as median value or percentage of women affected with 
cardiac dysfunction. Derived from Melchiorre et al.53 LV indicates left ventricular; 
and TVRI, total vascular resistance index.
Figure 2. Diagrammatic representation of the consequences of a relative 
imbalance of cardiovascular functional reserve and cardiovascular volume/
resistance load of pregnancy. Cardiovascular adaptation in normal 
pregnancy (green dotted line) results in subclinical cardiac dysfunction in 
a small but significant proportion of women at term. Poor cardiovascular 
adaptation to pregnancy (red dotted line) is more likely to occur with 
advanced maternal age, obesity, and other risk factors. Depending on the 
cardiovascular load of pregnancy (normal load: green solid line, excessive 
load: red solid line), different preeclampsia (PE) phenotypes will manifest, 
such as early or late PE.
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used interchangeably with those obtained by echocardiog-
raphy. However, the difference in agreement between various 
techniques may be overcome if technology-specific reference 
ranges are used.60 Initial studies using these monitors have 
suggested cardiac indices may be helpful in the management 
of hypertensive disorders of pregnancy.73,75
Placental biomarkers with cardiovascular effects, such as 
sFlt-1 and PIGF (placenta growth factor), are valuable in diag-
nosis of preeclampsia.76,77 Zeisler et al77 recently demonstrated 
that a maternal sFlt-1:PlGF ratio with a cutoff of <38 can ex-
clude the development of preeclampsia within 1 week with a 
negative predictive value of 99%, 80% sensitivity, and 78% 
specificity. A prospective pilot study of normotensive and hy-
pertensive pregnant women showed that the addition of bi-
ophysical cardiovascular indices to sFlt-1:PlGF significantly 
improved detection of hypertensive disorders of pregnancy.73 
Interestingly, these biomarkers seem to be elevated long after 
birth and delivery of the placenta and are related to long-term 
adverse maternal cardiovascular outcome.78
Cardiac assessment may also prove useful for guiding 
antihypertensive therapy and improving outcomes for women 
with preeclampsia.79–82 The choice of antihypertensive agent 
varies between national guidelines despite the fact that drugs 
of choice have vastly different mechanisms of action and side 
effect profiles. For instance, labetalol is the first line drug for 
treatment of pregnancy hypertension in United Kingdom.83 
Beta-blockers have negative inotropic and chronotropic 
effects, and any cardiologist would not usually choose such 
an agent for a hypertensive patient with low CO and increased 
vascular resistance—typical of early/severe preeclampsia.53,82 
In a randomized study of nonpregnant patients, Taler et al84 
demonstrate superior blood pressure control using a treatment 
algorithm and serial hemodynamic measurements compared 
with clinical judgment alone. It is difficult to imagine why 
these findings should not be applicable to women with hyper-
tensive disorders of pregnancy. The use of diuretics in women 
with preeclampsia had been an abandoned practice until a 
recent trial of nifedipine versus nifedipine plus furosemide 
demonstrated that diuretic use reduced the need for additional 
antihypertensive medication in preeclampsia.85 Diuretic use is 
likely to have been most beneficial in women with features 
of volume overload and less significant vascular resistance—
typical of late/mild preeclampsia.71 Cardiovascular profiling 
of hypertensive women may explain why similar drug com-
parisons yield variable results in different drug trials, as well 
as lack of consensus, on optimal antihypertensive manage-
ment despite several randomized trials.81,82,86–90
Combining biochemical tests and biophysical markers of 
cardiovascular function may allow for improved prediction of 
preeclampsia onset as well as peripartum maternal morbidity 
and postpartum cardiovascular disease. The most widely 
studied model for predicting adverse maternal outcomes is 
the fullPIERS (Preeclampsia Integrated Estimate of Risk) risk 
prediction model, which has been validated for different pre-
eclampsia subtypes and various resource setting.91,92 Although 
the fullPIERS model show modest prediction capabilities, 
the most influential variables used in the model are actually 
clinical features of cardiovascular decompensation such as 
chest pain, dyspnea, or low oxygen saturation. Assessment 
of cardiac function to better identify women who are at risk 
of pulmonary edema is not entirely without biological plausi-
bility because recent evidence suggests women who develop 
pulmonary edema have impaired diastolic dysfunction.68,93 
Major complications of preeclampsia, such as pulmonary 
edema, eclampsia, and cerebrovascular incidents, are for-
tunately rare but often have devastating maternal sequelae. 
These severe complications of preeclampsia are often prevent-
able with adequate blood pressure control, appropriate fluid 
management, and magnesium sulfate prophylaxis. Although 
management and prevention strategies are relatively simple, it 
is still a challenge to identify patients under risk so that they 
may receive a closer observation and treatment, which may be 
avoided in women at low risk of these complications. Profiling 
of cardiac function in women with preeclampsia during the 
immediate postnatal period and investigating its associations 
with short- and long-term postpartum complications would be 
an important step for establishing the role of cardiac assess-
ment in postpartum preeclampsia management.
Cardiovascular System in the Immediate 
Postpartum Period
The obstetric cure for preeclampsia has remained the same 
for several decades—scheduled iatrogenic birth. Immediately 
after birth, resolution of preeclampsia symptoms occurs con-
comitantly with reduction in stroke volume, CO, and mean 
arterial pressure.94 These symptoms and signs reach an equi-
librium and return to healthy pregnancy ranges within 3 to 
4 days, except for total vascular resistance and mean arterial 
pressure which remain significantly higher compared with 
controls, despite generally having systolic and diastolic blood 
pressure levels in the normal range—supporting the clinical 
paradigm that birth cures preeclampsia. However, longitudinal 
assessment of preeclampsia reveals that ≈50% of women have 
persistent hypertension and increased rates of nocturnal, am-
bulatory, and masked hypertension at 12 weeks postpartum.95,96 
The significance of persistent postpartum hypertension was 
underlined in a recent large cohort study by Behrens et al10 
which showed a high rate of antihypertensive medication use 
within a year of hypertensive pregnancy when compared with 
normotensive pregnancy (11% versus 0.5%, respectively). In 
the same cohort study, the cumulative incidence of hyperten-
sion within 10 years of delivery was significantly higher for 
young women (20–29 years) after preeclampsia when com-
pared with older women (40–49 years) with a nonpreeclamp-
tic pregnancy. Thus, a woman in her 20s with preeclampsia 
has a worse cardiovascular prognosis within 10 years of de-
livery compared with a woman twice her age.  Notably, the 
highest risk for development of chronic hypertension is within 
the first few years after birth (Figure 3). This reinforces the 
relative importance of preeclampsia as a stronger risk factor 
for cardiovascular disease than even smoking.
The impact of preeclampsia on a woman’s life is far from 
just being a risk factor for heart disease. Up to 40% of women 
do not get pregnant again after early-onset preeclampsia preg-
nancy—presumably because of their experience of serious 
pregnancy morbidity.97 Increased rates of hospital readmis-
sion, poor mental health, increased fatigue, and impaired so-
cial functioning in the postpartum period—up to 3 years after 
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the index pregnancy—are all associated with early/severe 
preeclampsia.98,99 For the mother, the immediate postpartum 
period is fraught with problems relating to care of new-born 
and factors such as low socioeconomic status, belonging to 
an ethnic minority, and having vaginal delivery are associ-
ated with nonattendance to postpartum visits.100 A possible 
solution to nonattendance would be empowering women to 
care for themselves. Home monitoring of blood pressure has 
been suggested as a safe, effective, and economical way of 
follow-up with women with hypertensive disorders of preg-
nancy.101,102 It is reasonable to assume similar efficacy during 
the postpartum period.103 However, blood pressure values and 
incidence of severe hypertension differ with home and clinic 
monitoring during pregnancy, and optimal cutoffs for action is 
subject to debate currently.104 Although preeclampsia should 
be regarded as an important risk factor for cardiovascular di-
sease in women, it also presents a unique opportunity to iden-
tify and potentially intervene to ameliorate the adverse effects 
of preeclampsia on immediate postpartum maternal health.
Aging After Preeclampsia: The Long-Term 
Consequences
In addition to a globally increased risk of cardiovascular di-
sease, a history of preeclampsia is also associated with 6 to 7× 
increased hazard of having recurrent ischemic attack within a 
year of developing acute coronary syndrome.105 Women with 
recurrent preeclampsia are characterized by a shorter life-span 
(48.9 versus 51.9 years), increased hazard of ischemic heart di-
sease (hazard ratio, 3.30), and stroke (hazard ratio, 5.10).13 The 
risk estimates for cardiovascular diseases and mortality differ 
for women with various subtypes of hypertensive disorders 
(eclampsia, preeclampsia, gestational hypertension) with more 
severe forms corresponding to higher risk.106–108 A recent sys-
tematic review produced aggregate data to show that recurrent 
preeclampsia is associated with increased rates of hypertension, 
ischemic heart disease, heart failure, cerebrovascular accident, 
and hospitalization because of cardiovascular disease.107 The 
persistence and immediacy of findings, such as asymptomatic 
heart failure, remodeling, or masked hypertension, make them 
unique markers for identifying women at greatest risk.
So, is elective schedule birth really a cure for pree-
clampsia? Evidence from cohort studies suggest otherwise 
with an increased risk of heart failure with preserved ejec-
tion fraction and also present for chronic kidney disease.108–110 
These long-term consequences of preeclampsia may poten-
tially be explained by the fact that both organs are affected 
in the acute phase of the disease. However, recent studies 
suggest that preeclampsia may also increase the risk of de-
mentia.111 Ciampa et al112 demonstrated vascular remodeling, 
inflammation, neuronal growth, and alterations in signal-
ing proteins in the cerebrospinal fluid of women with pre-
eclampsia (excluding eclampsia). Cerebral biomarkers of 
axonal injury and neuronal damage (such as the neurofilament 
light chain) not only predict preeclampsia with an accuracy 
similar to established angiogenic factors but are also elevated 
at 1-year postpartum.113–115 Persistent neuronal damage may 
be associated with vascular remodeling, potentially explaining 
white matter damage, increased risk of dementia, and vascular 
reactivity observed in elderly women with a history of pree-
clampsia.116–118 These recent studies investigating the associa-
tion of preeclampsia with both cardiovascular dysfunction and 
vascular dementia create a strong argument against the notion 
preeclampsia is cured by delivering the placenta/birth.
Left ventricular hypertrophy, coronary artery disease, heart 
failure, and stroke exhibit later presentation, more severe phe-
notypes, and worse prognosis in women compared with men. 
Depite this, there is a paucity of research focused on developing 
effective screening, follow-up, and intervention strategies for 
women after preeclampsia—despite presenting an unique op-
portunity for early intervention.119–123 The American Heart 
Association now recognizes that women with a history of pre-
eclampsia face an increased risk of stroke, heart disease, and 
deep venous thrombosis in the 5 to 15 years after pregnancy.124 
The American Heart Association recommends that at-risk 
individuals should educate themselves about cardiovascular 
disease risk reduction, such as smoking cessation, improved 
diet, and regular exercise. It is likely that more sophisticated 
assessment of cardiovascular function in the postnatal period 
may better identify women who are going to develop short 
and long-term cardiovascular morbidity.125 These studies are 
urgently required to facilitate the appropriate long-term car-
diovascular follow-up and entry into therapeutic trials to ame-
liorate the outcome. One such study in progress is PHOEBE 
(In women with preterm pre-eclampsia does planned de-
livery improve postpartum maternal cardiac function through 
attenuation of myocardial ischaemia at time of disease?; 
PHOENIX-3 [Pre-eclampsia in Hospital: Early Induction or 
Expectant Management]), which is a randomized trial in se-
vere preterm preeclampsia where women will all have a de-
tailed cardiovascular assessment (including echocardiography 
and cardiac biomarker evaluation) at 6 months postpartum. It is 
envisaged that the PHOEBE trial should be able to identify the 
optimal biomarkers to screen and identify postpartum cardio-
vascular morbidity (https://ukctg.nihr.ac.uk/trials/trial-details/
trial-details?trialNumber=ISRCTN01879376).
Figure 3. Hazard ratios for chronic hypertension by severity of 
preeclampsia and time since pregnancy according the national register 
cohort study by Behrens et al.10 Hazard ratios compare rates of chronic 
hypertension among women with hypertensive disorders of pregnancy 
and delivery <34 gestational wk (orange), delivery at 34–36 wk (green), and 
delivery ≥37 gestational wk (black).
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Conclusions
The risk factors for preeclampsia are cardiovascular in nature, 
cardiovascular signs and symptoms predominate in the clin-
ical syndrome of preeclampsia, and cardiovascular morbidity 
persists for decades after preeclampsia. All of these make a 
strong case for the involvement of the maternal cardiovascular 
system in the pathogenesis of preeclampsia (Figure 4). The 
pathogenesis of preeclampsia has always known to be a con-
sequence of placental damage secondary to oxidative stress or 
hypoxia resulting in the release in a maternal systemic antian-
giogenic imbalance.126 Preeclampsia was originally recognized 
by the presence of eclamptic fits before knowledge of signs and 
symptoms of the disorder led to a clinical severity-based clas-
sification. The latter has now been superseded to a temporal 
classification according to the gestation of onset of preeclamp-
sia—as early/late or preterm/term preeclampsia. In the future, 
cardiovascular phenotyping of preeclampsia is likely to prove 
more clinically useful. A better understanding of maternal car-
diovascular function in pregnancy would allow improved pre-
diction and diagnosis of preeclampsia, guide antihypertensive 
therapy, and improve clinical outcomes for women with pre-
eclampsia. The magnitude of cardiovascular dysfunction in 
preeclampsia is better understood when it is evident that hy-
pertensive disorders of pregnancy are a stronger factor for the 
postnatal development of cardiovascular and cerebrovascular 
disease than smoking alone. A strong focus on better postnatal 
cardiovascular assessment after preeclampsia is required so as 
not to waste a unique opportunity to alter disease trajectory and 
improve health inequalities in the cardiovascular and cerebro-
vascular health of women. 
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